Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Neurology|March 15, 2020
Evaluation of efficacy and tolerability of first-line therapies in NMOSDJulien Poupart, Jonathan Giovannelli, Romain Deschamps, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2021
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?Caroline Papeix, Julie Mazoyer, Elisabeth Maillart, et al.
Multiple Sclerosis and Related Disorders|February 28, 2026
Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosisVito Ag Ricigliano, Doriana Landi, Marine Boudot de la Motte, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2022
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?Zélia Poullet, Julie Pique, Adil Maarouf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 4, 2026
Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for multiple sclerosis: A report of three casesPhilippe Nicolas, Ysoline Beigneux, Anne-Marie Guennoc, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 5, 2023
Time to steroids impacts visual outcome of optic neuritis in MOGADJulie Rode, Julie Pique, Adil Maarouf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 15, 2025
Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC studyRyan Ramdani, Julie Pique, Romain Deschamps, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 12, 2021
Perturbed Microbiota/Immune Homeostasis in Multiple SclerosisDelphine Sterlin, Martin Larsen, Jehane Fadlallah, et al.
Journal of Neuroinflammation|March 3, 2022
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort studyStanislas Demuth, Maxime Guillaume, Bertrand Bourre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 17, 2025
Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patientsChloé Comet, Guillaume Jouvenot, Bertrand Bourre, et al.
Pageof 14